THE EFFICACY OF PHARMACOTHERAPY IN PATIENTS WITH OSTEOARTHROSIS OF THE KNEE JOINTS WITH ABERRANT 6-SULFATEXYMELATONIN EXCRETION PROFILE
Humeniuk O.V. , Stanislavchuk M.A.
Summary. Summary. We studied the efficacy of pharmacotherapy in patients with osteoarthrosis (OA) of knee joints with aberrant production of melatonin. The OA patients with normal excretion of 6-sulfatexymelatonin (6-SMT) treated with a standard pharmacotherapy (diclofenac sodium, glucosamine hydrochloride, chondroitin sulfate) presented with a better pattern of clinical parameters (Lequesne, HAQ, WOMAC, KOOS indices) than did OA subjects with aberrant 6-SMT excretion profile. At Week 12 of treatment, the OA patients with low-excretion of 6-SMT had a proportion of WOMAC20 non-responders 1.7 times higher than those among subjects with normal 6-SMT excretion. The inclusion of melatonin (3 mg/day) in the treatment regimen of OA patients with aberrant 6-SMT excretion profile improved the sleep quality, reduced depression, increased the course of clinical indices (Lequesne, HAQ, WOMAC, KOOS) and tripled the chances of gaining WOMAC20.
Leave a comment